CHARLOTTE, N.C., Jan. 11, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported the preliminary results of a European Phase IIb trial of Droxidopa, an orally available synthetic amino acid for the treatment of neurogenic orthostatic hypotension.
